字幕表 動画を再生する
RESOURCES
RESOURCES AND
RESOURCES AND AS
RESOURCES AND AS OF
RESOURCES AND AS OF TODAY
RESOURCES AND AS OF TODAY CORONAVIRUS
RESOURCES AND AS OF TODAY CORONAVIRUS HAS
RESOURCES AND AS OF TODAY CORONAVIRUS HAS BEEN
RESOURCES AND AS OF TODAY CORONAVIRUS HAS BEEN TO
RESOURCES AND AS OF TODAY CORONAVIRUS HAS BEEN TO 18
CORONAVIRUS HAS BEEN TO 18
CORONAVIRUS HAS BEEN TO 18 COUNTRIES.
COUNTRIES.
COUNTRIES. GEORGIA4@
COUNTRIES. GEORGIA4@ IS
COUNTRIES. GEORGIA4@ IS A
COUNTRIES. GEORGIA4@ IS A PART
COUNTRIES. GEORGIA4@ IS A PART OF
COUNTRIES. GEORGIA4@ IS A PART OF THE
COUNTRIES. GEORGIA4@ IS A PART OF THE RACE
COUNTRIES. GEORGIA4@ IS A PART OF THE RACEO
GEORGIA4@ IS A PART OF THE RACEO
GEORGIA4@ IS A PART OF THE RACEO DEVELOP
GEORGIA4@ IS A PART OF THE RACEO DEVELOP A
GEORGIA4@ IS A PART OF THE RACEO DEVELOP A VACCINE
GEORGIA4@ IS A PART OF THE RACEO DEVELOP A VACCINE AND
GEORGIA4@ IS A PART OF THE RACEO DEVELOP A VACCINE AND DEKALB
DEVELOP A VACCINE AND DEKALB
DEVELOP A VACCINE AND DEKALB COUNTY
DEVELOP A VACCINE AND DEKALB COUNTY COMPANY
DEVELOP A VACCINE AND DEKALB COUNTY COMPANY BELIEVES
DEVELOP A VACCINE AND DEKALB COUNTY COMPANY BELIEVES IT
DEVELOP A VACCINE AND DEKALB COUNTY COMPANY BELIEVES IT HAS
COUNTY COMPANY BELIEVES IT HAS
COUNTY COMPANY BELIEVES IT HAS AN
COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE
COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE BECAUSE
COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE BECAUSE IT
COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE BECAUSE IT HAS
AN ADVANTAGE BECAUSE IT HAS
AN ADVANTAGE BECAUSE IT HAS QUITE
AN ADVANTAGE BECAUSE IT HAS QUITE A
AN ADVANTAGE BECAUSE IT HAS QUITE A LONG
AN ADVANTAGE BECAUSE IT HAS QUITE A LONG TRACK
AN ADVANTAGE BECAUSE IT HAS QUITE A LONG TRACK RECORD.
QUITE A LONG TRACK RECORD.
QUITE A LONG TRACK RECORD. >>
QUITE A LONG TRACK RECORD. >> WE
QUITE A LONG TRACK RECORD. >> WE WANTED
QUITE A LONG TRACK RECORD. >> WE WANTED TO
QUITE A LONG TRACK RECORD. >> WE WANTED TO LEARN
QUITE A LONG TRACK RECORD. >> WE WANTED TO LEARN MORE
>> WE WANTED TO LEARN MORE
>> WE WANTED TO LEARN MORE ABOUT
>> WE WANTED TO LEARN MORE ABOUT THE
>> WE WANTED TO LEARN MORE ABOUT THE PROCESS
>> WE WANTED TO LEARN MORE ABOUT THE PROCESS AND
>> WE WANTED TO LEARN MORE ABOUT THE PROCESS AND JOE
>> WE WANTED TO LEARN MORE ABOUT THE PROCESS AND JOE HENKE
ABOUT THE PROCESS AND JOE HENKE
ABOUT THE PROCESS AND JOE HENKE STOPPED
ABOUT THE PROCESS AND JOE HENKE STOPPED BY
ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR
ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR A
ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR A LAB
ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR A LAB REPORT.
STOPPED BY FOR A LAB REPORT.
STOPPED BY FOR A LAB REPORT. >>
STOPPED BY FOR A LAB REPORT. >> Reporter:
STOPPED BY FOR A LAB REPORT. >> Reporter: CURRENTLY
STOPPED BY FOR A LAB REPORT. >> Reporter: CURRENTLY A
STOPPED BY FOR A LAB REPORT. >> Reporter: CURRENTLY A RISK
>> Reporter: CURRENTLY A RISK
>> Reporter: CURRENTLY A RISK OF
>> Reporter: CURRENTLY A RISK OF VACCINES
>> Reporter: CURRENTLY A RISK OF VACCINES FOR
>> Reporter: CURRENTLY A RISK OF VACCINES FOR THE
>> Reporter: CURRENTLY A RISK OF VACCINES FOR THE VIRUS
>> Reporter: CURRENTLY A RISK OF VACCINES FOR THE VIRUS IS
OF VACCINES FOR THE VIRUS IS
OF VACCINES FOR THE VIRUS IS BEING
OF VACCINES FOR THE VIRUS IS BEING TESTED
OF VACCINES FOR THE VIRUS IS BEING TESTED OR
OF VACCINES FOR THE VIRUS IS BEING TESTED OR READY
OF VACCINES FOR THE VIRUS IS BEING TESTED OR READY TO
OF VACCINES FOR THE VIRUS IS BEING TESTED OR READY TO BE
BEING TESTED OR READY TO BE
BEING TESTED OR READY TO BE TESTED
BEING TESTED OR READY TO BE TESTED AND
BEING TESTED OR READY TO BE TESTED AND SOME4@
BEING TESTED OR READY TO BE TESTED AND SOME4@ ARE
BEING TESTED OR READY TO BE TESTED AND SOME4@ ARE VIRUSES
TESTED AND SOME4@ ARE VIRUSES
TESTED AND SOME4@ ARE VIRUSES SIMILAR
TESTED AND SOME4@ ARE VIRUSES SIMILAR TO
TESTED AND SOME4@ ARE VIRUSES SIMILAR TO CORONAVIRUS
TESTED AND SOME4@ ARE VIRUSES SIMILAR TO CORONAVIRUS WHICH
SIMILAR TO CORONAVIRUS WHICH
SIMILAR TO CORONAVIRUS WHICH COULD
SIMILAR TO CORONAVIRUS WHICH COULD SPEED
SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP
SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP THE
SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP THE PROCESS
SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP THE PROCESS AND
COULD SPEED UP THE PROCESS AND
COULD SPEED UP THE PROCESS AND SOME
COULD SPEED UP THE PROCESS AND SOME WHO
COULD SPEED UP THE PROCESS AND SOME WHO HAS
COULD SPEED UP THE PROCESS AND SOME WHO HAS SIX
COULD SPEED UP THE PROCESS AND SOME WHO HAS SIX EXISTING
SOME WHO HAS SIX EXISTING
SOME WHO HAS SIX EXISTING RELATIONSHIPS
SOME WHO HAS SIX EXISTING RELATIONSHIPS WITH
SOME WHO HAS SIX EXISTING RELATIONSHIPS WITH HEALTH
SOME WHO HAS SIX EXISTING RELATIONSHIPS WITH HEALTH 4@
RELATIONSHIPS WITH HEALTH 4@
RELATIONSHIPS WITH HEALTH 4@ OFFICIALS
RELATIONSHIPS WITH HEALTH 4@ OFFICIALS DOESN'T
RELATIONSHIPS WITH HEALTH 4@ OFFICIALS DOESN'T HURT4@
RELATIONSHIPS WITH HEALTH 4@ OFFICIALS DOESN'T HURT4@ EITHER
OFFICIALS DOESN'T HURT4@ EITHER
OFFICIALS DOESN'T HURT4@ EITHER >>
OFFICIALS DOESN'T HURT4@ EITHER >> Reporter:
OFFICIALS DOESN'T HURT4@ EITHER >> Reporter: SCIENTISTS
OFFICIALS DOESN'T HURT4@ EITHER >> Reporter: SCIENTISTS LIKE
OFFICIALS DOESN'T HURT4@ EITHER >> Reporter: SCIENTISTS LIKE RV
>> Reporter: SCIENTISTS LIKE RV
>> Reporter: SCIENTISTS LIKE RV INFECT
>> Reporter: SCIENTISTS LIKE RV INFECT CELLS
>> Reporter: SCIENTISTS LIKE RV INFECT CELLS IN
>> Reporter: SCIENTISTS LIKE RV INFECT CELLS IN VIRUSES
>> Reporter: SCIENTISTS LIKE RV INFECT CELLS IN VIRUSES THEY
INFECT CELLS IN VIRUSES THEY
INFECT CELLS IN VIRUSES THEY ARE
INFECT CELLS IN VIRUSES THEY ARE SETTING
INFECT CELLS IN VIRUSES THEY ARE SETTING AND
INFECT CELLS IN VIRUSES THEY ARE SETTING AND USE
INFECT CELLS IN VIRUSES THEY ARE SETTING AND USE THEIR
ARE SETTING AND USE THEIR
ARE SETTING AND USE THEIR FINDINGS
ARE SETTING AND USE THEIR FINDINGS AS4@
ARE SETTING AND USE THEIR FINDINGS AS4@ THEY
ARE SETTING AND USE THEIR FINDINGS AS4@ THEY DEVELOP
FINDINGS AS4@ THEY DEVELOP
FINDINGS AS4@ THEY DEVELOP VACCINES.
VACCINES.
VACCINES. THEY
VACCINES. THEY USE
VACCINES. THEY USE AN
VACCINES. THEY USE AN APPROACH
VACCINES. THEY USE AN APPROACH THAT
VACCINES. THEY USE AN APPROACH THAT THE
THEY USE AN APPROACH THAT THE
THEY USE AN APPROACH THAT THE CEO
THEY USE AN APPROACH THAT THE CEO SAYS
THEY USE AN APPROACH THAT THE CEO SAYS IT
THEY USE AN APPROACH THAT THE CEO SAYS IT IS
THEY USE AN APPROACH THAT THE CEO SAYS IT IS EFFICIENT
THEY USE AN APPROACH THAT THE CEO SAYS IT IS EFFICIENT IN
CEO SAYS IT IS EFFICIENT IN
CEO SAYS IT IS EFFICIENT IN CREATING
CEO SAYS IT IS EFFICIENT IN CREATING A
CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE
CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE TO
CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE TO BE
CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE TO BE TESTED
CREATING A VACCINE TO BE TESTED
CREATING A VACCINE TO BE TESTED AND
CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE
CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS
CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS IT
CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS IT MAKES
CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS IT MAKES A
AND 4@EFFECTIVE AS IT MAKES A
AND 4@EFFECTIVE AS IT MAKES A VACCINE
AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S
AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A
AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A SINGLE
AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A SINGLE DOSE
AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A SINGLE DOSE AND
VACCINE THAT'S A SINGLE DOSE AND
VACCINE THAT'S A SINGLE DOSE AND SET
VACCINE THAT'S A SINGLE DOSE AND SET OF
VACCINE THAT'S A SINGLE DOSE AND SET OF MULTIPLE
VACCINE THAT'S A SINGLE DOSE AND SET OF MULTIPLE DOSES.
SET OF MULTIPLE DOSES.
SET OF MULTIPLE DOSES. GENERALLY
SET OF MULTIPLE DOSES. GENERALLY THEY
SET OF MULTIPLE DOSES. GENERALLY THEY CAN
SET OF MULTIPLE DOSES. GENERALLY THEY CAN CREATE
SET OF MULTIPLE DOSES. GENERALLY THEY CAN CREATE A
GENERALLY THEY CAN CREATE A
GENERALLY THEY CAN CREATE A BASIS
GENERALLY THEY CAN CREATE A BASIS FOR
GENERALLY THEY CAN CREATE A BASIS FOR A
GENERALLY THEY CAN CREATE A BASIS FOR A VACCINE
GENERALLY THEY CAN CREATE A BASIS FOR A VACCINE WITHIN
BASIS FOR A VACCINE WITHIN
BASIS FOR A VACCINE WITHIN THREE
BASIS FOR A VACCINE WITHIN THREE MONTHS
BASIS FOR A VACCINE WITHIN THREE MONTHS AND
BASIS FOR A VACCINE WITHIN THREE MONTHS AND BEGIN
BASIS FOR A VACCINE WITHIN THREE MONTHS AND BEGIN ANIMAL
THREE MONTHS AND BEGIN ANIMAL
THREE MONTHS AND BEGIN ANIMAL TESTING.
TESTING.
TESTING. >>
TESTING. >> GOING
TESTING. >> GOING BEYOND
TESTING. >> GOING BEYOND THAT
TESTING. >> GOING BEYOND THAT IN
TESTING. >> GOING BEYOND THAT IN THE
>> GOING BEYOND THAT IN THE
>> GOING BEYOND THAT IN THE CLINICAL
>> GOING BEYOND THAT IN THE CLINICAL IS
>> GOING BEYOND THAT IN THE CLINICAL IS A
>> GOING BEYOND THAT IN THE CLINICAL IS A FUNCTION
>> GOING BEYOND THAT IN THE CLINICAL IS A FUNCTION OF
>> GOING BEYOND THAT IN THE CLINICAL IS A FUNCTION OF WHAT
CLINICAL IS A FUNCTION OF WHAT
CLINICAL IS A FUNCTION OF WHAT REGULATORY
CLINICAL IS A FUNCTION OF WHAT REGULATORY AUTHORITIES
REGULATORY AUTHORITIES
REGULATORY AUTHORITIES DETERMINE
REGULATORY AUTHORITIES DETERMINE WHAT
REGULATORY AUTHORITIES DETERMINE WHAT IS
REGULATORY AUTHORITIES DETERMINE WHAT IS APPROPRIATE
DETERMINE WHAT IS APPROPRIATE
DETERMINE WHAT IS APPROPRIATE PROTOCOL
DETERMINE WHAT IS APPROPRIATE PROTOCOL TO
DETERMINE WHAT IS APPROPRIATE PROTOCOL TO FOLLOW
DETERMINE WHAT IS APPROPRIATE PROTOCOL TO FOLLOW AND
PROTOCOL TO FOLLOW AND
PROTOCOL TO FOLLOW AND DEPENDING
PROTOCOL TO FOLLOW AND DEPENDING ON
PROTOCOL TO FOLLOW AND DEPENDING ON THAT
PROTOCOL TO FOLLOW AND DEPENDING ON THAT THAT
PROTOCOL TO FOLLOW AND DEPENDING ON THAT THAT WILL
DEPENDING ON THAT THAT WILL
DEPENDING ON THAT THAT WILL DETERMINE
DEPENDING ON THAT THAT WILL DETERMINE HOW
DEPENDING ON THAT THAT WILL DETERMINE HOW IT
DEPENDING ON THAT THAT WILL DETERMINE HOW IT WILL
DEPENDING ON THAT THAT WILL DETERMINE HOW IT WILL GO
DEPENDING ON THAT THAT WILL DETERMINE HOW IT WILL GO TO
DETERMINE HOW IT WILL GO TO
DETERMINE HOW IT WILL GO TO HUMANS.
HUMANS.
HUMANS. >>
HUMANS. >> 4@THEY
HUMANS. >> 4@THEY HAVE
HUMANS. >> 4@THEY HAVE VACCINES
HUMANS. >> 4@THEY HAVE VACCINES FOR
HUMANS. >> 4@THEY HAVE VACCINES FOR OTH
>> 4@THEY HAVE VACCINES FOR OTH
>> 4@THEY HAVE VACCINES FOR OTH VIRUSES
>> 4@THEY HAVE VACCINES FOR OTH VIRUSES AND
>> 4@THEY HAVE VACCINES FOR OTH VIRUSES AND VACCINES
>> 4@THEY HAVE VACCINES FOR OTH VIRUSES AND VACCINES ENTRY
VIRUSES AND VACCINES ENTRY
VIRUSES AND VACCINES ENTRY CLINICAL
VIRUSES AND VACCINES ENTRY CLINICAL CLOUD
VIRUSES AND VACCINES ENTRY CLINICAL CLOUD TILES.
CLINICAL CLOUD TILES.
CLINICAL CLOUD TILES. WITH
CLINICAL CLOUD TILES. WITH THE
CLINICAL CLOUD TILES. WITH THE CORONAVIRUS
CLINICAL CLOUD TILES. WITH THE CORONAVIRUS TIME
CLINICAL CLOUD TILES. WITH THE CORONAVIRUS TIME IS
CLINICAL CLOUD TILES. WITH THE CORONAVIRUS TIME IS OF
WITH THE CORONAVIRUS TIME IS OF
WITH THE CORONAVIRUS TIME IS OF THE
WITH THE CORONAVIRUS TIME IS OF THE ESSENCE
WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND
WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND THEY
WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND THEY CAN
WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND THEY CAN USE
THE ESSENCE AND THEY CAN USE
THE ESSENCE AND THEY CAN USE RESEARCH.
RESEARCH.
RESEARCH. >>
RESEARCH. >> THIS
RESEARCH. >> THIS VIRUS
RESEARCH. >> THIS VIRUS IS
RESEARCH. >> THIS VIRUS IS SIMILAR
RESEARCH. >> THIS VIRUS IS SIMILAR TO
>> THIS VIRUS IS SIMILAR TO
>> THIS VIRUS IS SIMILAR TO SARS
>> THIS VIRUS IS SIMILAR TO SARS 4@AND
>> THIS VIRUS IS SIMILAR TO SARS 4@AND WE
>> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN
>> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN BUILD
>> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN BUILD UPON
>> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN BUILD UPON TH
SARS 4@AND WE CAN BUILD UPON TH
SARS 4@AND WE CAN BUILD UPON TH FOUNDATION
SARS 4@AND WE CAN BUILD UPON TH FOUNDATION OF
SARS 4@AND WE CAN BUILD UPON TH FOUNDATION OF LITERATURE
SARS 4@AND WE CAN BUILD UPON TH FOUNDATION OF LITERATURE THAT
FOUNDATION OF LITERATURE THAT
FOUNDATION OF LITERATURE THAT EXISTS
FOUNDATION OF LITERATURE THAT EXISTS PERTAINING
FOUNDATION OF LITERATURE THAT EXISTS PERTAINING TO
EXISTS PERTAINING TO
EXISTS PERTAINING TO DEVELOPMENT
EXISTS PERTAINING TO DEVELOPMENT OF
EXISTS PERTAINING TO DEVELOPMENT OF THE
EXISTS PERTAINING TO DEVELOPMENT OF THE SARS
EXISTS PERTAINING TO DEVELOPMENT OF THE SARS VACCINE
DEVELOPMENT OF THE SARS VACCINE
DEVELOPMENT OF THE SARS VACCINE AND
DEVELOPMENT OF THE SARS VACCINE AND APPLY
DEVELOPMENT OF THE SARS VACCINE AND APPLY IT
DEVELOPMENT OF THE SARS VACCINE AND APPLY IT FOR
DEVELOPMENT OF THE SARS VACCINE AND APPLY IT FOR THIS
DEVELOPMENT OF THE SARS VACCINE AND APPLY IT FOR THIS OUTBREAK.
AND APPLY IT FOR THIS OUTBREAK.
AND APPLY IT FOR THIS OUTBREAK. >>4@
AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING
AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING ALONGSIDE
AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING ALONGSIDE THEM
AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING ALONGSIDE THEM IS
>>4@ WORKING ALONGSIDE THEM IS
>>4@ WORKING ALONGSIDE THEM IS BRAVO
>>4@ WORKING ALONGSIDE THEM IS BRAVO MAX
>>4@ WORKING ALONGSIDE THEM IS BRAVO MAX ARE
>>4@ WORKING ALONGSIDE THEM IS BRAVO MAX ARE WUHAN
>>4@ WORKING ALONGSIDE THEM IS BRAVO MAX ARE WUHAN VACCINE
BRAVO MAX ARE WUHAN VACCINE
BRAVO MAX ARE WUHAN VACCINE DEVELOPER
BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN
BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN THE
BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN THE EPICENTER
BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN THE EPICENTER OF
DEVELOPER IN THE EPICENTER OF
DEVELOPER IN THE EPICENTER OF THE
DEVELOPER IN THE EPICENTER OF THE OUTBREAK.
THE OUTBREAK.
THE OUTBREAK. THEY4@
THE OUTBREAK. THEY4@ ENTERED
THE OUTBREAK. THEY4@ ENTERED AN
THE OUTBREAK. THEY4@ ENTERED AN AGREEMENT
THE OUTBREAK. THEY4@ ENTERED AN AGREEMENT TO
THEY4@ ENTERED AN AGREEMENT TO
THEY4@ ENTERED AN AGREEMENT TO CREATE
THEY4@ ENTERED AN AGREEMENT TO CREATE A
THEY4@ ENTERED AN AGREEMENT TO CREATE A VACCINE.
CREATE A VACCINE.
CREATE A VACCINE. >>
CREATE A VACCINE. >> THEY
CREATE A VACCINE. >> THEY HAVE
CREATE A VACCINE. >> THEY HAVE A
CREATE A VACCINE. >> THEY HAVE A STRONG
>> THEY HAVE A STRONG
>> THEY HAVE A STRONG RELATIONSHIP
>> THEY HAVE A STRONG RELATIONSHIP WITH
>> THEY HAVE A STRONG RELATIONSHIP WITH THE
>> THEY HAVE A STRONG RELATIONSHIP WITH THE CHINESE
RELATIONSHIP WITH THE CHINESE
RELATIONSHIP WITH THE CHINESE CDC
RELATIONSHIP WITH THE CHINESE CDC AND
RELATIONSHIP WITH THE CHINESE CDC AND THE
RELATIONSHIP WITH THE CHINESE CDC AND THE CHINESE
RELATIONSHIP WITH THE CHINESE CDC AND THE CHINESE PUBLIC
CDC AND THE CHINESE PUBLIC
CDC AND THE CHINESE PUBLIC REGULATORY
CDC AND THE CHINESE PUBLIC REGULATORY OFFICIALS.
REGULATORY OFFICIALS.
REGULATORY OFFICIALS. AND
REGULATORY OFFICIALS. AND WORKING
REGULATORY OFFICIALS. AND WORKING TOGETHER
REGULATORY OFFICIALS. AND WORKING TOGETHER WE
REGULATORY OFFICIALS. AND WORKING TOGETHER WE THINK
AND WORKING TOGETHER WE THINK
AND WORKING TOGETHER WE THINK WE
AND WORKING TOGETHER WE THINK WE CAN
AND WORKING TOGETHER WE THINK WE CAN MOVE
AND WORKING TOGETHER WE THINK WE CAN MOVE MUCH
AND WORKING TOGETHER WE THINK WE CAN MOVE MUCH QUICKER
AND WORKING TOGETHER WE THINK WE CAN MOVE MUCH QUICKER ALONG
WE CAN MOVE MUCH QUICKER ALONG
WE CAN MOVE MUCH QUICKER ALONG WITH
WE CAN MOVE MUCH QUICKER ALONG WITH THE
WE CAN MOVE MUCH QUICKER ALONG WITH THE OTHER
WE CAN MOVE MUCH QUICKER ALONG WITH THE OTHER ENTITIES
WE CAN MOVE MUCH QUICKER ALONG WITH THE OTHER ENTITIES WE
WITH THE OTHER ENTITIES WE
WITH THE OTHER ENTITIES WE BROUGHT
WITH THE OTHER ENTITIES WE BROUGHT IN
WITH THE OTHER ENTITIES WE BROUGHT IN WITH
WITH THE OTHER ENTITIES WE BROUGHT IN WITH A
WITH THE OTHER ENTITIES WE BROUGHT IN WITH A CANDIDATE
WITH THE OTHER ENTITIES WE BROUGHT IN WITH A CANDIDATE FOR
BROUGHT IN WITH A CANDIDATE FOR
BROUGHT IN WITH A CANDIDATE FOR TESTING.
TESTING.
TESTING. >>
TESTING. >> I'M
TESTING. >> I'M TOLD
TESTING. >> I'M TOLD THE
TESTING. >> I'M TOLD THE TIMELINE
TESTING. >> I'M TOLD THE TIMELINE FOR
>> I'M TOLD THE TIMELINE FOR
>> I'M TOLD THE TIMELINE FOR THE
>> I'M TOLD THE TIMELINE FOR THE VACCINE
>> I'M TOLD THE TIMELINE FOR THE VACCINE COULD
>> I'M TOLD THE TIMELINE FOR THE VACCINE COULD BE
>> I'M TOLD THE TIMELINE FOR THE VACCINE COULD BE READY.
THE VACCINE COULD BE READY.
THE VACCINE COULD BE READY. IT
THE VACCINE COULD BE READY. IT COULD
THE VACCINE COULD BE READY. IT COULD BE
THE VACCINE COULD BE READY. IT COULD BE MONTHS
THE VACCINE COULD BE READY. IT COULD BE MONTHS OR
THE VACCINE COULD BE READY. IT COULD BE MONTHS OR MORE
THE VACCINE COULD BE READY. IT COULD BE MONTHS OR MORE THAN
IT COULD BE MONTHS OR MORE THAN
IT COULD BE MONTHS OR MORE THAN 1
IT COULD BE MONTHS OR MORE THAN 1 YEAR.
IT COULD BE MONTHS OR MORE THAN 1 YEAR. 4@
1 YEAR. 4@
1 YEAR. 4@ THE
1 YEAR. 4@ THE LARGEST
1 YEAR. 4@ THE LARGEST UNKNOWN
1 YEAR. 4@ THE LARGEST UNKNOWN IS
1 YEAR. 4@ THE LARGEST UNKNOWN IS HOW
1 YEAR. 4@ THE LARGEST UNKNOWN IS HOW LONG
THE LARGEST UNKNOWN IS HOW LONG
THE LARGEST UNKNOWN IS HOW LONG IT
THE LARGEST UNKNOWN IS HOW LONG IT WILL
THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE
THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE TO
THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE TO SEEK
THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE TO SEEK 4@4@GOVERN
IT WILL TAKE TO SEEK 4@4@GOVERN
IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL
IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO
IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE
IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE THE
IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE THE VACCINE
IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE THE VACCINE ON
APPROVAL TO USE THE VACCINE ON
APPROVAL TO USE THE VACCINE ON HUMANS.
HUMANS.
HUMANS. >>>
HUMANS. >>> THERE
HUMANS. >>> THERE ARE
HUMANS. >>> THERE ARE A
HUMANS. >>> THERE ARE A LOT
HUMANS. >>> THERE ARE A LOT OF
HUMANS. >>> THERE ARE A LOT OF STORIES
>>> THERE ARE A LOT OF STORIES
>>> THERE ARE A LOT OF STORIES CIRCULATING
>>> THERE ARE A LOT OF STORIES CIRCULATING ABOUT
>>> THERE ARE A LOT OF STORIES CIRCULATING ABOUT THE
CIRCULATING ABOUT THE
CIRCULATING ABOUT THE CORONAVIRUS
CIRCULATING ABOUT THE CORONAVIRUS AND
CIRCULATING ABOUT THE CORONAVIRUS AND MANY
CIRCULATING ABOUT THE CORONAVIRUS AND MANY ARE
CIRCULATING ABOUT THE CORONAVIRUS AND MANY ARE NOT
CORONAVIRUS AND MANY ARE NOT